A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
Principal Investigator
David Scott Miller, MD,
Status
Terminated
Date of Study Termination
January 05 2021
Disease Site
Gynecologic [GY]
Uterine Corpus
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is therapeutically equivalent to the combination of doxorubicin, cisplatin and paclitaxel (TAP) chemotherapy with regards to survival.
Patient Population
Patients must have primary Stage III or Stage IV (see FIGO staging—Appendix I) or recurrent endometrial carcinoma (see GOG Pathology Manual IV:1-4) whose potential for cure by radiation therapy or surgery alone or in combination is very poor.
Target Accrual
1350
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.